CVS Health Corp vs New York Times Co — how do they compare? CVS Health Corp trades at $88.26 (market cap $112.29B), while New York Times Co trades at $66.74 (market cap $10.74B). The key difference: CVS Health Corp is far larger — about 10.5× New York Times Co's market cap, and CVS Health Corp pays the higher dividend (3.03%). Which is the better fit depends on your goals — on Pluang, investors hold CVS Health Corp for 83 Days and New York Times Co for 81 Days on average.
| CVS | NYT | |
|---|---|---|
Market Cap | $112.29B | $10.74B |
Volume | 7,763,676 | 2,096,352 |
Sector | Health | Media |
52-Week High | $110.60 | $85.86 |
52-Week Low | $70.08 | $54.66 |
Typical Hold Time | 83 Days | 81 Days |
Enterprise Value | $174.64B | $10.14B |
Dividend Yield | 3.03% | 1.38% |
Signals from Pluang's Aura AI — not financial advice
CVS Health trades at $87.95, up 1.76% on the day, with a bullish technical signal and strong analyst support. Recent earnings beats in Q1 and Q2 2026, alongside steady revenue growth to $402.07B in 2025, highlight operational strength. The stock's valuation appears attractive with a P/E of 23.17 and P/S of 0.27, while a consensus price target of $111.20 suggests significant upside potential. Positive news includes Aetna's 2027 Medicare plan enhancements and a declared quarterly dividend.
The outlook for CVS remains positive, driven by earnings momentum and strategic initiatives in healthcare services. Key risks include reimbursement pressures and regulatory scrutiny, but Wall Street's 85% buy rating and institutional interest underscore confidence. Investors should weigh the stock's growth prospects against margin volatility and debt levels, with the current price offering a favorable entry point relative to targets.
The New York Times Company (NYT) trades at $64.90, up 1.3% with a bearish technical signal despite strong fundamental performance. Recent earnings beats and consistent revenue growth to $2.82 billion in 2025 highlight operational strength, though a shareholder lawsuit and AI copyright disputes present headwinds. Analyst consensus is mixed with a $84 price target suggesting 29% upside from current levels.
The stock offers value through earnings growth and dividend yield, but faces sentiment pressure from legal challenges and technical indicators. Key risks include litigation outcomes and competitive pressures in digital media, while institutional ownership trends and positive cash flow generation support the investment case for patient investors.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
Following its acquisition of Aetna in late 2018, CVS Health now provides an even more integrated healthcare-services offering for its members. Legacy CVS combined both the largest pharmacy benefit manager, processing over 2 billion adjusted claims annually, and a sizable pharmacy operation, including nearly 10,000 retail pharmacy locations primarily in the U.S. Adding a managed-care organization with 24 million medical members gives the company a strong position in the insurance industry and should help CVS better control overall healthcare costs for its clients.
Read more on CVS →New York Times Co is an American media company known for publishing its flagship newspaper, The New York Times. The company also operates the International New York Times newspaper, as well as digital properties such as nytimes and various smartphone applications. Circulation of The New York Times is the source of revenue for the company, followed by print and digital advertising and its paid digital-only subscription to The New York Times. The company has a daily print circulation of over 500,000 and 1,000,000 on Sundays. The source of growth for The New York Times is its digital subscription service, which has over 1,000,000 paid users.
Read more on NYT →